Lasers, 595-nm pulsed
dye and 1,064-nm
neodymium-doped
yttrium aluminum garnet (Nd:YAG), have been used successfully for the treatment of infantile
hemangiomas (IHs). Recently the use of a topical β-blocker, specifically
timolol maleate, has been promising in the treatment of IHs. The objective of this study was to compare the effectiveness of topical
timolol 5 mg/mL
solution with that of combined sequential dual-wavelength
laser in the treatment of IHs. Sixty children with IHs were divided randomly into two equal groups. Group 1 was treated with applications of
timolol drops (5 mg/mL) twice daily. Group 2 was treated with sequential pulsed
dye and
Nd:Yag laser. Treatments were performed every month for a maximum of six sessions. Efficacy was evaluated clinically and by measuring the average
hemoglobin level. A significant decrease in the average
hemoglobin level was determined in both groups and a dramatic response was observed in superficial
hemangiomas in the
timolol group. The
timolol group received treatment for an average of 4.0 ± 1.1 months and the
laser group for 5.5 ± 0.9 months. The degree of improvement of mixed
hemangiomas to
laser treatment was greater than that of the
timolol group. During 3 months of follow-up, no further improvement or relapse was reported in either group.
Timolol solution is a safe and effective alternative to
laser treatment in superficial
hemangiomas. In mixed
hemangiomas, the combined sequential 595-nm and 1,064-nm dual-wavelength
laser provided better results than
timolol solution because it penetrated deeply so that deep dermal blood vessels were reached.